Licogliflozin, a Dual SGLT1/2 Inhibitor is a potential treatment option for Polycystic ovary syndrome (PCOS). Polycystic ovary syndrome (PCOS), which affects 15% of women of fertile age, is characterized by hyperandrogenism and insulin resistance (IR) with compensatory hyperinsulinism.
The dual sodium-glucose co-transporter 1/2 inhibitor (SGLT1/2i) licogliflozin (LIK066) ameliorates hyperinsulinism in patients with diabetes and obesity.
Read full article on Medical Dialogues: [ Ссылка ]
#PCOS #fertilewomen #newdrug
Follow us on
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
LinkedIn: [ Ссылка ]
Website: [ Ссылка ]
Get the latest medical and heath news at medicaldialogues.in
